
Oxford Nanopore Technologies
Developing a new generation of nanopore-based electronic systems for analysis of single molecules.
- B2B
- manufacturing
- selling own inventory
- health
- biotechnology
- artificial intelligence
- hardware
- big data
- deep tech
- machine learning
- nanotech
- biotechnology
- dt and ls
- spinout
- core ai
- analytics
- ai applications
- genetics and genomics
- verified unicorns and $1b exits
- dna
- streaming
- verified thoroughbreds
- genome engineering
- nif defense security and resilience
- ai drug discovery
- techbio
- tech for biotech and pharma
- health diagnostics
- digital pharma
- techbio drug discovery
- nif health crisis preparedness
- health care information technology
- molecular
- nif biotech
- rna
- bia techbio uk
- sequencing
Date | Investors | Amount | Round |
---|---|---|---|
- | investor investor investor investor investor investor investor | €0.0 | round |
investor investor | €0.0 | round | |
investor | €0.0 | round | |
investor investor | €0.0 | round | |
investor investor | €0.0 | round | |
investor | €0.0 | round | |
investor investor investor investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
N/A | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor investor | €0.0 Valuation: €0.0 | round | |
investor investor investor | €0.0 Valuation: €0.0 | round | |
investor | €0.0 Valuation: €0.0 | round | |
N/A | €0.0 Valuation: €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
investor investor | €0.0 | round | |
investor investor investor investor investor | €0.0 Valuation: €0.0 | round | |
investor | €0.0 Valuation: €0.0 | round | |
N/A | €0.0 Valuation: €0.0 | round | |
investor | €0.0 | round | |
* | £50.0m | Post IPO Equity | |
Total Funding | 000k |




























USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% growth | 17 % | 49 % | (15 %) | 8 % | 20 % | 28 % | 27 % |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% EBITDA margin | (104 %) | (31 %) | (64 %) | (50 %) | (44 %) | (24 %) | (8 %) |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% profit margin | (125 %) | (46 %) | (91 %) | (80 %) | (65 %) | (43 %) | (22 %) |
EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
R&D % of revenue | 57 % | 33 % | 61 % | 54 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Oxford Nanopore Technologies is a biotech company that specializes in the development of nanopore sequencing technology. This technology is used to decode DNA and RNA, providing highly accurate genomic data. The company's technology is used by scientific researchers to answer questions about the biology of people, plants, animals, pathogens, and environments. It is also increasingly being used in applied settings such as healthcare and food safety.
The company's business model is based on selling its nanopore sequencing technology and related products, including flow cells, compatible devices, manual and automated library prep, and data analysis solutions. The technology provides real-time insights, allowing for faster results that don't require batching. This makes it accessible and affordable, with scalability that enables more use cases.
The company operates in the biotech market, serving clients in the scientific research community, healthcare sector, and food safety industry. Its technology is unique in that it offers any-length sequencing, from short to ultra-long native DNA and RNA reads. This provides richer insights as it captures more types of genetic variation.
In terms of financial performance, the company generates revenue through the sale of its products and services. It has also formed strategic partnerships, such as with Apple, to integrate its technology with the M3 silicon chip.
Keywords: Nanopore Sequencing, Genomic Data, Biotech, Scientific Research, Healthcare, Food Safety, DNA and RNA Decoding, Real-time Insights, Scalability, Technology Sales.
Tech stack
Investments by Oxford Nanopore Technologies
Edit